Of note and in line with previous observations, both Sotorasib and BI-3406 showed robust on-target efficacy when applied as monotherapy in various assays using KRAS G12C mutant MiaPaCa pancreatic cancer cells that was further enhanced by concomitant MEK inhibition with Binimetinib, while efficacy of BI-2852 was limited. Here, MAP2K7 is linked to pancreatic neoplasm.